Sana Biotechnology (NASDAQ:SANA) Trading 7.4% Higher Following Analyst Upgrade

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) rose 7.4% on Tuesday after Bank of America raised their price target on the stock from $6.00 to $7.00. Bank of America currently has a buy rating on the stock. Sana Biotechnology traded as high as $4.46 and last traded at $4.3620. Approximately 634,615 shares traded hands during mid-day trading, a decline of 57% from the average daily volume of 1,475,205 shares. The stock had previously closed at $4.06.

Other equities analysts have also recently issued reports about the stock. Citizens Jmp raised their target price on shares of Sana Biotechnology from $5.00 to $8.00 and gave the company a “market outperform” rating in a research note on Thursday, October 30th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sana Biotechnology in a research note on Monday, December 29th. Citigroup restated an “outperform” rating on shares of Sana Biotechnology in a research note on Thursday, October 30th. JMP Securities set a $8.00 target price on shares of Sana Biotechnology in a report on Thursday, October 30th. Finally, HC Wainwright reduced their price target on Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating for the company in a report on Friday, November 7th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $8.14.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of SANA. Marex Group plc acquired a new stake in Sana Biotechnology during the second quarter worth approximately $10,423,000. Vanguard Group Inc. lifted its holdings in Sana Biotechnology by 19.9% during the 3rd quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock worth $32,408,000 after purchasing an additional 1,517,474 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Sana Biotechnology by 180.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock valued at $7,581,000 after purchasing an additional 1,375,029 shares during the period. Baillie Gifford & Co. grew its holdings in Sana Biotechnology by 13.6% in the 3rd quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company’s stock valued at $40,600,000 after buying an additional 1,371,775 shares in the last quarter. Finally, Corient Private Wealth LLC increased its position in Sana Biotechnology by 264.7% during the 2nd quarter. Corient Private Wealth LLC now owns 1,136,000 shares of the company’s stock worth $3,101,000 after buying an additional 824,505 shares during the period. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Stock Up 7.6%

The stock has a fifty day moving average price of $4.30 and a two-hundred day moving average price of $3.99. The company has a market cap of $1.16 billion, a price-to-earnings ratio of -4.51 and a beta of 1.96.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.03. Analysts predict that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.